Merck & Co., Inc. Statement on Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices' Recommendation for Pneumococcal Vaccination in Immunocompromised Adults

Published: Jun 20, 2012

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today provided the following statement regarding the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP)'s updated recommendation for pneumococcal vaccine as a two vaccine regimen in adults with immunocompromising conditions, functional or anatomic asplenia, cerebral spinal fluid (CSF) leaks or cochlear implants.

Back to news